Biocorp (PAR:ALCOR) said today that its smart cap, Easylog, won CE Mark clearance for use with insulin delivery devices.
The company’s device turns traditional pen injectors into connected devices, capturing treatment information like dose, date and time of injection. Easylog transfers that data to a mobile app for patients to monitor.
“CE marking for Easylog is a significant step for Biocorp. Our ambition is to develop and market innovative devices boosting compliance, a key factor for the successful treatment of chronic conditions such as diabetes. Easylog device, which generates interest of many industrial players internationally, brings an extra dimension to the customization of treatments. We are particularly pleased to reach this milestone that confirms our pioneering position in the digitalization of drug delivery devices and will contribute to achieve our growth objectives,” chief operating officer Eric Dessertenne said in prepared remarks.
Biocorp reported that it plans to launch its Easylog product in the EU sometime in 2018 through the help of partnerships.
